Regorafenib (BAY 73-4506)

製品コードS1178 別名:Fluoro-Sorafenib

Regorafenib (BAY 73-4506)化学構造

分子量(MW):482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

サイズ 価格(税別)  
JPY 27888.00
JPY 19920.00
JPY 34860.00
JPY 78020.00
JPY 161020.00

製品安全説明書

VEGFR阻害剤の選択性比較

生物活性

製品説明 Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
ターゲット
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
体外試験

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B MWLBdI9xfG:|aYOgRZN{[Xl? MWOx5qCUPcLizszN MWK0PEBp NHrDR2VqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MVuyOlMzQTZyOB?=
PLC/PRF/5  MnjZRZBweHSxc3nzJGF{e2G7 NGLpOZUy6oDVNdMg{txO M1HBPVQ5KGh? M1f0OYlvcGmkaYTzJINmdGxiZ4Lve5Rp M4\u[FI3OzJ7NkC4
HepG2  MWDBdI9xfG:|aYOgRZN{[Xl? Ml\HNgKBmzYEoN88US=> NIDBfGw1QCCq NIL1SVBqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NWTaPIVROjZ|Mkm2NFg>
HEK293 M1;UbGZ2dmO2aX;uJGF{e2G7 M2m0TVAvPeLCid88US=> NH3OfIUzNzRxNjDo NVLSW3dvemWmdXPld{BIWlB5ODDlfJBz\XO|aX;u MXuyOVg2QDB|Mh?=
GEO MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfST2VvOC5yMT2yNEDPxE1? M{\VUlk3KGh? NEPXXmRFVVOR Mn3IbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXuyOVg{QDN7MR?=
SW48 Ml3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33OT|AvODFvMkCg{txO MXu5OkBp M{L1T2ROW09? NYHLbZZ6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnT1NlU5Ozh|OUG=
HT29 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljCNE4xOS1{MDFOwG0> NXPpdGhvQTZiaB?= NUPWNIU{TE2VTx?= M1nkUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVj1bWFtOjV6M{izPVE>
SW480 NFzBS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfhNE4xOS1{MDFOwG0> MVi5OkBp NUHId40yTE2VTx?= MmHFbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXS2RoVSOjV6M{izPVE>
SW620 NW\nVG9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TH[FAvODFvMkCg{txO NVLUN4pFQTZiaB?= MXzEUXNQ NVLvdVgxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MYWyOVg{QDN7MR?=
HCT116 MkfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[yOnRIOC5yMT2yNEDPxE1? NHvM[Wc6PiCq MWjEUXNQ NF3O[5VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MljHNlU5Ozh|OUG=
LOVO M3nYNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XvUlAvODFvMkCg{txO MVe5OkBp MnPlSG1UVw>? NHPDXlJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHTWbpYzPTh|OEO5NS=>
HCT150 NIOweIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTDOZk4OC5yMT2yNEDPxE1? NEL2Uoc6PiCq MW\EUXNQ NUDjO2VRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3T2NlI2QDN6M{mx
SW48-CR NYG2OZlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPQV5c3OC5yMT2yNEDPxE1? NFHSNY06PiCq M2XKSmROW09? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVi4e2Z7OjV6M{izPVE>
GEO-CR M2mxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XPfVAvODFvMkCg{txO NXXPRXhIQTZiaB?= M1zOdmROW09? M4TBSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MV:yOVg{QDN7MR?=
KB-31 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXaUGQ2UUN3ME21MlXDuTBwMzDuUS=> MV2yOVc2OzN4MR?=
KB-G2 NYXCeGNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvxZpNJUUN3ME25MlHDuTBwMTDuUS=> MkXwNlU4PTN|NkG=
LLC-PK1 NX3lOmJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HVfmlEPTB;NEKuNOKyOy5{IH7N NET6dGUzPTd3M{O2NS=>
LLC-PK1/MRP2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3rTWM2OD16Mj60xtEzNjdibl2= M331dVI2PzV|M{[x
HEK293 NEHUTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrkdYVnUUN3ME2xNU4xyrFzLkKgcm0> MnzxNlU4PTN|NkG=
HEK293/OATP1B1 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHLT4dMUUN3ME22MlLDuTBwMzDuUS=> NFS1eIYzPTd3M{O2NS=>
HROC18 NIDvRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfYR5R6UUN3ME2xMlMh|ryP NIfpVmszPTNyOUmxOC=>
HROC24 NVG4WINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRwNjFOwG0> MWGyOVMxQTlzNB?=
HROC43 NWjzUZdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TNT2lEPTB;NT6zJO69VQ>? NVXHPHdDOjV|MEm5NVQ>
HROC46 NWD6N5cyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XKcWlEPTB;Mj60JO69VQ>? M4D2clI2OzB7OUG0
RJ345 M{H2V2Z2dmO2aX;uJGF{e2G7 NYLVSm42OC53L{Wg{txO NFOxOZUzPCCq NYnVWnFyTE2VTx?= MlfmbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u M2G2dlI2OjV|OUm0
RJ348 NUjBd|VQTnWwY4Tpc44hSXO|YYm= M3vLSVAvPS93IN88US=> M{jielI1KGh? NH;qbYdFVVOR NVXiUFJQcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MmXCNlUzPTN7OUS=
MCF-7 M1HIeWZ2dmO2aX;uJGF{e2G7 NHGyVncxNjVxNTFOwG0> NGfjNIozPCCq NVqyT5JSTE2VTx?= NUHmSIpWcW6qaXLpeJMhfGinIHPlcIwhdWmpcnH0bY9v MYiyOVI2Ozl7NB?=
MDA-MB-231 M3XRXWZ2dmO2aX;uJGF{e2G7 NY\odGtOOC53L{Wg{txO M4nsdVI1KGh? Mlr5SG1UVw>? NHKwOYxqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NEfC[o0zPTJ3M{m5OC=>
HT15 NEjZdHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHxUnFkOS1{MDFOwG0> M4XTZ|Q5KGh? MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M13qOVI2ODdzMEG4
DLD1 M4fUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HBO|EuOjBizszN MV[0PEBp MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NELnbFYzPTB5MUCxPC=>
HT-29 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxMVIxKM7:TR?= NXy4UVZTPDhiaB?= MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYrTdVFZOjVyN{GwNVg>
Hct-116 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PFXlEuOjBizszN Mm\GOFghcA>? NHvxTFJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUjEcmN1OjVyN{GwNVg>
HT15 MUnBdI9xfG:|aYOgRZN{[Xl? M2qwNVEuOTBizszN MoTPOFghcA>? MmH1bY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXPLZmNwOjVyN{GwNVg>
DLD1 NH7HbWpCeG:ydH;zbZMhSXO|YYm= MUmxMVExKM7:TR?= MWe0PEBp MUPpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYHPO5FGOjVyN{GwNVg>
HT-29 M{[zNWFxd3C2b4Ppd{BCe3OjeR?= MmfXNU0yOCEQvF2= Mnm5OFghcA>? MYTpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NELFfXAzPTB5MUCxPC=>
Hct-116 NWjZc4lnSXCxcITvd4l{KEG|c3H5 NXLiNmp3OS1zMDFOwG0> MlPiOFghcA>? NHjHbIZqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1zJSFI2ODdzMEG4
GBM5 MYXBdI9xfG:|aYOgRZN{[Xl? NXn0TnNVOC534pETNU4x6oDLzszN NFrU[3gzPCCq MorCSG1UVw>? NGK3fXlqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> M3LTclI1QTFzMkG1
GBM6 MUHBdI9xfG:|aYOgRZN{[Xl? MV:wMlXjiJNzLkFihKnPxE1? NIjvdI0zPCCq NYfkXHJwTE2VTx?= NF\HUGVqdnSncnHjeJMhf2m2aDDsZZBifGmwaXKgeI8hcW6mdXPlJINmdGxiZHXheIg> NYm3Z|czOjR7MUGyNVU>
GBM12 M2XVSGFxd3C2b4Ppd{BCe3OjeR?= M3\DNlAvPeLCk{GuNQKBkc7:TR?= NIi5OnMzPCCq MVPEUXNQ NYLCeHdxcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp NFfPPJQzPDlzMUKxOS=>
GBM14  NIPPSmpCeG:ydH;zbZMhSXO|YYm= M4PQclAvPeLCk{GuNQKBkc7:TR?= Mk\yNlQhcA>? NI\ufHlFVVOR NV3iPIRVcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp NYPoPZl7OjR7MUGyNVU>
Hep3B M4TxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvxXYwy6oDVMj61xsDPxE1? MlKzNlQwPDhxN{KgbC=> NF;UTW9qdmirYnn0d{Bk\WyuIHfyc5d1cA>? MWKyOFg5PTh7MB?=
PLC/PRF/5  MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2K2SlHjiJN{LkZCpO69VQ>? Ml3tNlQwPDhxN{KgbC=> NXLmSpVYcW6qaXLpeJMh[2WubDDndo94fGh? NWnycJloOjR6OEW4PVA>
HepG2  Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHONgKBmzJwNdMg{txO MXOyOE81QC95MjDo MYrpcohq[mm2czDj[YxtKGe{b4f0bC=> MVuyOFg5PTh7MB?=
HCT116  NFK1d|JHfW6ldHnvckBCe3OjeR?= M1\aVFExNzJyL{SwJO69VQ>? MoW2NlQhcA>? MUXpcoR2[2W|IGDVUWEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MV2yOFc3OzZzMR?=
Lim2405 M4LvdmZ2dmO2aX;uJGF{e2G7 MmDMOFAh|ryP M3WyU|I1KGh? Mn7ibY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MmK3NlQ4PjN4MUG=
LoVo M{\nU2Z2dmO2aX;uJGF{e2G7 NEXhXXM1OCEQvF2= MVmyOEBp MUnpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NW\uPWNSOjR5NkO2NVE>
Lim1215 Mo\tSpVv[3Srb36gRZN{[Xl? NUixOZpnPDBizszN NFLDeIQzPCCq NF\EWoFqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NILQb5ozPDd4M{[xNS=>
SW48 NXe3Z5dOTnWwY4Tpc44hSXO|YYm= M{[zcFQxKM7:TR?= NWPleFF1OjRiaB?= MXPpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M2X1WVI1PzZ|NkGx
RKO  MoXjSpVv[3Srb36gRZN{[Xl? M{XQ[VQxKM7:TR?= NXviOXMzOjRiaB?= NX;PSoZ5cW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MonWNlQ4PjN4MUG=
SW837 M3\xNWZ2dmO2aX;uJGF{e2G7 M2\uTFQxKM7:TR?= MWGyOEBp Mm\kbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NUX5SXBLOjR5NkO2NVE>
SW1463 MWHGeY5kfGmxbjDBd5NigQ>? NGTkdZU1OCEQvF2= MWKyOEBp NUHpZVdIcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NYW4b|JEOjR5NkO2NVE>
SW480 NV3XS4RSTnWwY4Tpc44hSXO|YYm= M3e1XVQxKM7:TR?= MXiyOEBp MlLqbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ MUmyOFc3OzZzMR?=
Vaco432 NU\LdoVbTnWwY4Tpc44hSXO|YYm= M4j4flQxKM7:TR?= Ml7KNlQhcA>? NHHxemxqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? M{fRPFI1PzZ|NkGx
Vaco400 NEHTZpBHfW6ldHnvckBCe3OjeR?= MXe0NEDPxE1? MYeyOEBp MYTpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> M4T1XVI1PzZ|NkGx
DLD1 MoHySpVv[3Srb36gRZN{[Xl? NHXpNIs1OCEQvF2= MkT5NlQhcA>? NUeyTXdFcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MlHlNlQ4PjN4MUG=
HT29  MlnPSpVv[3Srb36gRZN{[Xl? NWHnOIZlPDBizszN MlHSNlQhcA>? Moj3bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ NXn3d4g6OjR5NkO2NVE>
PLC/PRF/5  NXrQeZA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\CNgKBmzYEtV2= NHz3[nczPC92OD:3NkBp MofDbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NX;RcIJOOjNzNkmxOFg>
HepG2 NGnqd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmx5qCUPcL3TR?= M4rz[|I1NzR6L{eyJIg> MUfpcohq[mm2czDj[YxtKGe{b4f0bC=> MYOyN|E3QTF2OB?=
Hep3B  MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDGU21WOeLCk{ZCuW0> NXqzT3hwOjRxNEivO|IhcA>? M3W0fIlvcGmkaYTzJINmdGxiZ4Lve5Rp NWHnbFZ3OjNzNkmxOFg>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
細胞試験: [1]
+ 展開
  • 細胞株: GIST 882 and TT cells
  • 濃度: 5 nM-10 μM
  • 反応時間: 96 hours
  • 実験の流れ: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • 製剤: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • 投薬量: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • 投与方法: Orally
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 97 mg/mL (200.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
いい結果が出るために、混じった後、直ちに使うと推めます。
5mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 482.82
化学式

C21H15ClF4N4O3

CAS No. 755037-03-7
保管
別名 Fluoro-Sorafenib

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

VEGFRシグナル伝達経路

VEGFR Inhibitors with Unique Features

相関VEGFR製品

Tags: Regorafenib (BAY 73-4506)を買う | Regorafenib (BAY 73-4506) ic50 | Regorafenib (BAY 73-4506)供給者 | Regorafenib (BAY 73-4506)を購入する | Regorafenib (BAY 73-4506)費用 | Regorafenib (BAY 73-4506)生産者 | オーダーRegorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506)化学構造 | Regorafenib (BAY 73-4506)分子量 | Regorafenib (BAY 73-4506)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID